Clinical Trials Browser

Phase 2 × Hematologic Neoplasms × isatuximab × Clear all

NCT05873205 2026-04-02

Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation

Phase 2 Active not recruiting

Other hematologic neoplasm

Hematologic Neoplasms